1. Home
  2. STTK vs TRVG Comparison

STTK vs TRVG Comparison

Compare STTK & TRVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.05

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$2.97

Market Cap

278.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
TRVG
Founded
2016
2005
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
278.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STTK
TRVG
Price
$3.05
$2.97
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$4.00
$3.96
AVG Volume (30 Days)
355.1K
54.0K
Earning Date
11-06-2025
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
$614,486,683.00
Revenue This Year
N/A
$18.36
Revenue Next Year
N/A
$9.18
P/E Ratio
N/A
$102.50
Revenue Growth
N/A
14.41
52 Week Low
$0.69
$2.02
52 Week High
$3.38
$5.83

Technical Indicators

Market Signals
Indicator
STTK
TRVG
Relative Strength Index (RSI) 67.21 44.70
Support Level $2.82 $2.87
Resistance Level $3.30 $3.15
Average True Range (ATR) 0.24 0.11
MACD -0.00 0.00
Stochastic Oscillator 74.76 20.78

Price Performance

Historical Comparison
STTK
TRVG

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.

Share on Social Networks: